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Abstract
Checkpoint kinase 2 (CHK2) is an important serine/threonine kinase in the cellular response to DNA damage. A fragment-
based screening campaign using a combination of a high-concentration AlphaScreenTM kinase assay and a biophysical
thermal shift assay, followed by X-ray crystallography, identified a number of chemically different ligand-efficient CHK2
hinge-binding scaffolds that have not been exploited in known CHK2 inhibitors. In addition, it showed that the use of these
orthogonal techniques allowed efficient discrimination between genuine hit matter and false positives from each individual
assay technology. Furthermore, the CHK2 crystal structures with a quinoxaline-based fragment and its follow-up compound
highlight a hydrophobic area above the hinge region not previously explored in rational CHK2 inhibitor design, but which
might be exploited to enhance both potency and selectivity of CHK2 inhibitors.
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Introduction
Checkpoint kinase 2 (CHK2) is a serine/threonine kinase
crucial in the activation of signal transduction pathways involved
in the cellular response to DNA damage caused by external agents
[1,2,3,4]. In response to double strand DNA breaks, CHK2 is
activated through initial phosphorylation on Thr68 by the DNA
damage sensor ataxia-telangiectasia mutated (ATM) [5,6] and
subsequent trans-autophosphorylation on Thr383 and Thr387
and cis-autophosphorylation on Ser516 [7,8,9,10]. In its fully
activated state CHK2 is known to phosphorylate a variety of
substrates involved in DNA-repair, cell cycle control and
apoptosis. For example, CHK2 phosphorylation of BRCA1
promotes the repair of double strand DNA breaks [11], while
phosphorylation of the transcription factor forkhead box protein
M1 enhances homologous recombination and base excision repair
mechanisms [12]. Alternatively, CHK2 promotes apoptosis by
phosphorylation of the transcription factor E2F1 [13] and by
phosphorylation of the p53 interaction partner HDMX, which
stabilises p53 and results in a G1 cell cycle arrest and cell death
[14,15].
The therapeutic value of CHK2 inhibition is still unclear, but
selective CHK2 inhibitors could be potentially beneficial in a
variety of contexts. In several cancer cell lines, CHK2 is highly
activated, suggesting a crucial role in survival. Therefore,
inhibition of CHK2 could have the potential to exert an anti-
cancer effect through disruption of DNA-repair pathways pivotal
for the survival of cancer cells with high levels of activated CHK2
[1,4,16]. Indeed, siRNA knockdown of CHK2 and selective
CHK2 inhibition with the small molecule inhibitor PV1019 (1,
Figure 1) both resulted in an antiproliferative effect in cancer cell
lines [17].
However, CHK2 inhibition is mostly being explored in the
context of DNA damaging cancer therapies, such as genotoxic
agents and ionising radiation. In normal cells, p53-mediated
apoptosis is one of the causes of cell death in response to double
strand DNA breaks caused by ionising radiation or cytotoxic
chemotherapy [18]. Because approximately half of all cancers
have a defective p53 tumour suppression function [19], CHK2
inhibition could selectively reduce p53-mediated apoptosis in
normal tissue and therefore mitigate the side-effects of such
therapies in patients with this profile [4,20]. Experiments with four
small molecule CHK2 inhibitors of different chemical classes have
demonstrated such a radioprotective effect in isolated mouse
thymocytes and human T-cells [17,21,22,23]. In addition, it has
been shown that Chk22/2 transgenic mice are resistant to
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apoptosis after exposure to ionising radiation [3,24] and, in
contrast to p53-deficient mice, no increased tumorigenesis has
been observed in these CHK2-deficient mice.
On the other hand, it has been proposed that CHK2 inhibition
in p53-deficient tumor cells could sensitise the cells to DNA
damaging therapies through abrogation of the G2 checkpoint
[4,25]. The validity of this hypothesis remains unclear, because
although both CHK2 siRNA knock-down experiments and
CHK2 inhibition by the small molecule inhibitor PV1019 showed
potentiation of the cytotoxicity of topotecan and campothecan in
ovarian cancer cell lines [17], no such effects have been observed
with the inhibitors VRX0466617 (2) [22] and CCT241533 (3)
[23,26] (Figure 1) in combination with genotoxic agents. However,
it was recently demonstrated that the potent and selective CHK2
inhibitor 3 potentiates the cytotoxicity of poly(ADP-ribose)
polymerase (PARP) inhibitors such as AG14447 and olaparib,
potentially providing new therapeutic options for targeted cancer
therapy [26].
To date, several ATP-competitive CHK2 inhibitors have been
discovered including the guanylhydrazones such as PV1019 (1)
[17,27], the isothiazole carboxamidines exemplified by
VRX0466617 (2) [22,28], an indoloazepine derivative of hyme-
nialdisine (4) [29,30] and the 2-arylbenzimidazole-5-carboxamides
(5) [21,31] (Figure 1). In addition, several dual checkpoint kinase 1
(CHK1)/CHK2 inhibitors with a high affinity for CHK2 have
been reported, such as the staurosporine analogue UCN-01 (6)
[32,33], the thiophene-2-carboxamide AZD7762 (7) [34,35], the
N-(1H-pyrazol-5-yl)pyrazin-2-amine LY2606368 (8) [36,37], the
1H- [1,2]diazepino[4,5,6-cd]indol-6(5H)-one PF-00477736 (9) [38]
and XL-844 (structure undisclosed) [39] (Figure 1). Furthermore,
we have recently reported two different series of potent CHK2
inhibitors, the 3,5-disubstituted-2-aminopyridines such as (10) [40]
and the 2-(quinazolin-2-yl)phenols which include the potent and
selective CHK2 inhibitor, 3, mentioned above [23,26]. Both series
originated from biochemical screening of focussed libraries, but in
order to generate additional medicinal chemistry starting points
we embarked on parallel fragment screening of CHK2.
Fragment-based drug discovery (FBDD), which in the last 10
years has become established as an attractive approach in drug
discovery, involves the screening of a relatively small library,
typically of 500 to 2000 compounds of low complexity and low
molecular weight [41,42,43,44]. Although fragments tend to bind
in a highly ligand-efficient manner, their binding is often weak and
fragment screening usually relies on sensitive biophysical technol-
ogies such as nuclear magnetic resonance (NMR), X-ray
crystallography, surface plasmon resonance (SPR) or differential
scanning fluorimetry (DSF)/thermal shift assays. However, frag-
ment screening using high-concentration biochemical assays is
increasingly being employed [45,46,47].
In this article, we describe the screening of our fragment library
against CHK2 using a combination of a high-concentration
Amplified Luminescent Proximity Homogeneous Assay Screen
(AlphaScreenTM) kinase assay and a thermal shift assay. A detailed
comparison of the AlphaScreenTM and thermal shift screening
data revealed that this combination of technologies can help
prioritise the most promising fragments by the efficient identifi-
cation of false positives from each individual screen. In addition,
we present the protein-ligand crystal structures of nine fragment
hits, all of which bind to the hinge in the CHK2 ATP-binding site.
We show that with a focussed similarity search against a
moderately sized library of 71,000 lead-like compounds, we were
able to identify inhibitors with improved potency with respect to
their different parent fragment hits, whilst maintaining ligand
efficiency. The crystal structure of a quinoxaline-based follow-up
compound shows it extending deeply into a previously unexplored
hydrophobic pocket above the hinge region, an area that is
inaccessible in CHK1 due to its larger gatekeeper +2 residue and
therefore could offer a way to enhance CHK2/CHK1 selectivity
in future CHK2 inhibitors.
Results and Discussion
The ICR Fragment Library
In order to compile an in-house fragment library, we identified
14,533 compounds from vendor libraries that passed criteria based
on the Rule-of-Three [48] outlined in the materials and methods
section and were available in quantities of 50 mg or greater.
However, in keeping with the experience of others [49] and based
on our own experience in the template screening of checkpoint
kinase 1 [47], we did not adhere completely to the Rule-of-Three.
In particular, we applied a maximum molecular weight filter of
300 Da with an additional 20 Da for compounds containing
specific groups (F, Cl, SO2), in order to capture compounds with
sufficient size and functionality to allow reliable detection in a
high-concentration biochemical assay and to provide synthetic
handles for further optimization. Based on diverse subset selection
[50] and removal of compounds with undesirable structural
moieties, a final selection of 1,869 fragments was purchased. This
initial fragment library was screened to identify inhibitors of
CHK2, which additionally allowed us to assess the performance of
this first iteration of the library. In parallel, we conducted an
analysis of fragment solubility and integrity using nephelometry
and LC-MS, respectively, as fragment screening and subsequent
crystallographic analysis usually requires experiments at high
fragment concentrations [51].
High Concentration Biochemical Fragment Screening
To identify fragments binding in the ATP-binding-site of
CHK2, we screened the in-house fragment library consisting of
1869 compounds, as described above, against full-length CHK2
using an AlphaScreenTM kinase assay, in which inhibition of full-
length CHK2 was measured by a reduction in the phosphorylation
of a CDC25C peptide (Figure S1). Because of the generally weak
affinity of fragments, the assay was carried out at a high compound
concentration (300 mM). All fragments were assayed in triplicate
and fragments with a percentage inhibition greater than 50% in
two out of three measurements were defined as hits, yielding 45
initial hits in total, a hit rate of 2.4%. All 45 hits were confirmed by
re-assaying them under the same conditions. To eliminate
potential false positives due to aggregation of poorly soluble
fragments, or owing to interference with the AlphaScreenTM
signal, the hits were assayed by including 0.01% (v/v) TritonTM X-
100 in the assay buffer, and in the presence of phosphorylated
rather than unphosphorylated peptide substrate, respectively. The
average robust Z’ for the confirmation assays was 0.9. No
aggregating fragments were detected, but 17 out of the 45 hits
Figure 1. Chemical structures of published CHK2 inhibitors. 1, The guanylhydrazone PV1019; 2, the isothiazole carboxamidine VRX0466617;
3, the 2-(quinazolin-2-yl-phenol inhibitor CCT241533; 4, the indoloazepine derivative of hymenialdisine; 5, a 2-arylbenzimidazole-5-carboxamide; 6,
the staurosporine analog UCN-01; the dual CHK1/CHK2 inhibitors 7, AZD7762; 8, LY2606368; 9, PF-00477736; and 10, a 2-aminopyridine inhibitor
CHK2 inhibitor.
doi:10.1371/journal.pone.0065689.g001
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from the primary screen were found to interfere with the
AlphaScreenTM assay, with an inhibition of more than 20% of
the AlphaScreenTM signal. A further eight fragments showed some
interference, but this did not account for all of the inhibition seen.
For the twenty fragments that showed no interference, a
microfluidic mobility shift assay (see materials and methods) was
used to determine the IC50 values, which ranged between 2.7 and
944 mM. The final confirmed hit rate for the assay was 1.1%.
Thermal Shift Assay
In parallel, we screened the fragment library against the kinase
domain of CHK2 (CHK2-KD, residues 210-531) using a thermal
shift assay. In a thermal shift assay, the folding stability of a target
protein is measured by its thermally-induced unfolding [52]. An
increase in melting temperature of a protein in the presence of a
ligand is used to identify ligand binding, assuming that the bound
ligand stabilizes the target protein and therefore increases the
energy required for its thermal unfolding. The thermal unfolding
of CHK2-KD was measured using the fluorescent dye SYPROH
OrangeTM, which is sensitive to its environment and preferentially
binds to hydrophobic patches that are typically exposed upon
protein unfolding. To identify the hit threshold, we calculated the
standard deviation (SD) of the melting temperature of CHK2 in
the presence of a ligand (Tm, ligand) for each plate. Ligands with a
Tm, ligand value of more than 2 standard deviations above the mean
Tm, ligand for each plate in at least one of the duplicates were
defined as hits. We calculated the mean change in melting
temperature from duplicate measurements (DTm, ligand) by
subtracting the mean melting temperature of six reference samples
of protein without ligand (Tm, 0) from the melting temperature of
CHK2 samples with ligand (Tm, ligand). This hit criterion resulted
in 63 thermal shift hits with DTm, ligand varying between 0.9 and
7.0uC, representing a hit rate of 3.4%.
Comparison of AlphaScreenTM and Thermal Shift Results
Comparing the primary AlphaScreenTM and thermal shift
results shows that the data can be grouped into four broad
categories (Figure 2A). The first category (Figure 2A, shown in red)
comprises 14 mutual hits in the AlphaScreenTM and thermal shift
assays, 12 of which could be confirmed by IC50 determination in
the mobility shift assay. We observed a very good correlation of the
IC50 and DTm, ligand values (Figure 2B). None of these compounds
was flagged as insoluble by nephelometry. Compound 11 was
identified as the top-ranking hit in both assays with a mean IC50 of
2.760.2 mM and a DTm, ligand of 7.060.8uC (Figure 3, Table 1).
Two fragments in this category showed interference in the counter
screen and were removed from the hit list. The final hit rate from
combining both screens followed by the interference assay was
therefore 0.64%.
The second category (displayed in yellow in Figure 2A) consists
of fragments classed as actives in the biochemical screen, but with
a DTm, ligand below the hit threshold in the thermal shift assay.
Analysis of the interference data shows that the majority of these
fragments display interference with the AlphaScreenTM signal, and
eight were flagged as insoluble by nephelometry.
The third category (shown in orange in Figure 2A) contains the
fragments classed as hits in the thermal shift assay, but as inactives
in the AlphaScreenTM kinase assay. Therefore this category is
likely to include the fragments that bind to the CHK2 kinase
domain, but as they do not affect the activity of the enzyme, they
may bind non-specifically, or to sites other than the ATP-binding
site. However, so far we have not obtained evidence of fragments
binding in such second sites. Notably, this category contains three
compounds that generated Tm, ligand values of more than 5
standard deviations from the mean, which is equal or better than
those of the best hits in the first category. These compounds were
soluble as analyzed by nephelometry; however, consistent with the
initial screening data, follow-up experiments revealed IC50 values
considerably higher than those of the mutual hits in category 1
(Figure S2). In addition, two of the three compounds failed to yield
crystals in co-crystallization experiments with CHK2-KD and
were not further progressed. Out of the 49 fragments in this
category, 13 were determined to be insoluble by nephelometry.
The fourth and largest category includes all compounds falling
below the hit thresholds in both assays, thus comprising the
inactives in both screens (shown in grey in Figure 2A).
Structural Characterisation of the Fragment Hits
We have obtained protein-ligand structures of nine fragment
hits by co-crystallizing them with the CHK2-KD protein also used
in the thermal shift assay (Figure 3). Eight fragments belong to the
category of mutual hits identified in both the AlphaScreenTM and
the thermal shift assays. They comprise the benzimidazotriazole
11, the resorcinol 12, two quinoxalines (13 and 14), the amino-
quinazoline 15, and three pyrazole-containing fragments (16, 17
and 18). Compound 19 was the only fragment of the three
fragments from the third category (those with a strong thermal
shift but minimal biochemical activity) that yielded a crystal
structure. All nine fragment hits bind to the hinge region in the
CHK2 ATP-binding pocket (Figure 4), although the relatively
poor ligand efficiency of compound 19 makes it an unattractive
fragment to follow-up (Table 1); therefore, we removed it from
further analyses. Although the eight mutual fragment hits all bind
to CHK2-KD with one or more of the canonical hydrogen-bond
interactions (Figure 4), there are some interesting differences in the
way they bind to the hinge.
The binding of compound 11, which is the top-ranking hit in
both the AlphaScreenTM kinase and thermal shift assays, is
complicated as it can adopt different tautomers. Thus, compound
11 interacts with the hinge either through hydrogen bonds with
the backbone carbonyl of Glu302 and the backbone amide of
Met304, or via hydrogen bonds of both the backbone amide and
carbonyl groups of Met304. Unfortunately, the structural data do
not allow discrimination between these possibilities and it may
even be the case that a mixture of tautomers is present in the
crystal. In addition to the interactions with the hinge region,
compound 11 interacts via a mediating water molecule with the
side-chain hydroxyl of Thr367, located at the start of the
activation loop just before the DFG motif.
By contrast, the resorcinol compound 12 forms only a single
hydrogen bond with the hinge through one of its hydroxyl groups
and the backbone amide of Met304. An additional weak
interaction is made via a CHO-interaction with the backbone
carbonyl of Met304. Furthermore, compound 12 interacts directly
with the side chain of Thr367, instead of via a mediating water
molecule as seen in the compound 11-bound structure.
The two quinoxaline fragments, compounds 13 and 14, bind in
a very similar way, with a hydrogen bond to the hinge between
one of the ring nitrogen atoms and the amide nitrogen of Met304
and a CHO-interaction with the backbone carbonyl of Glu302.
Compound 13 forms an additional hydrogen bond with the
protein between its amide N2 atom and the carbonyl group of
Met304. Furthermore, the furan ring in compound 13 binds to the
surface defined by Leu303 and Met304, an area associated with
productive hydrophobic interactions and probed in the previously-
described 2-aminopyridine CHK2 inhibitors [40], such as 2-
amino-5-(2,3-dihydrothieno[3,4-b] [1,4]dioxin-5-yl)-N-(2-(di-
methylamino)ethyl)nicotinamide (10), shown in Figure 1 and 5A.
Fragment Screening of CHK2
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Similar to compound 11, compound 14 also interacts with Thr367
via a mediating water molecule, which is not present in the
compound 13-bound structure. The electron density of compound
14 indicates that the oxygen atom of its urea moiety points
towards the carbonyl group of Met304. This is surprising, as it
seems an unfavorable interaction; however, it may account for the
slight difference in potency between the two quinoxaline
fragments.
The amino-quinazoline compound 15 also interacts via one of
its ring nitrogen atoms with the amide group of Met304, but in
Figure 2. Fragment screening data from biochemical and thermal shift assays. (A) Comparison showing the primary AlphaScreenTM data
plotted along the vertical axis as percentage inhibition, and the thermal shift data plotted along the horizontal axis as the number of standard
deviations from the mean Tm, ligand for each plate. The hit threshold for the AlphaScreen
TM is indicated by the horizontal line, the threshold for hits in
the thermal shift assay by the vertical line. Hits in AlphaScreenTM and thermal shift are displayed in yellow and orange respectively. Mutual hits are
shown in red. Fragments that are inactive in both assays are coloured grey. Each fragment is shown as an individual point. Fragments showing
interference in the AlphaScreenTM are indicated as triangles. Fragments confirmed in crystallography are shown as squares. (B) Comparison of the IC50
and DTm, ligand values for the screening hits. The mobility shift IC50 values are plotted on the vertical axis against the mean DTm, ligand for each of the
non-interfering mutual hits from the primary screen. The figures were generated in Microsoft Excel.
doi:10.1371/journal.pone.0065689.g002
Figure 3. Chemical structures of the nine fragment hits confirmed in crystallography. The benzimidazotriazole compound 11 is the most
active hit in both the AlphaScreenTM and thermal shift assay. Compound 12 is a resorcinol, compounds 13 and 14 both contain a quinoxaline
scaffold, compound 15 is an aminoquinazoline, compounds 16, 17 and 18 are fragments containing a pyrazole moiety, and compound 19 is a
pyridine.
doi:10.1371/journal.pone.0065689.g003
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Table 1. Crystallographically confirmed fragment hits.
Crystallographically
validated hits
AlphaScreenTM
(percentage inhibition)a
Mobility shift IC50
(mM)b
Tm, ligand (standard deviations
from the
plate mean)c DTm, ligand (6C)d
Ligand
Efficiency(kcal
mol21 HA21)e
11 91.460.4 2.760.2 5.8 7.060.8 0.64
12 58.261.7 85.667.9 2.9 3.0f 0.47
13 76.161.1 11.762.0 5.7 5.660.3 0.36
14 59.561.9 36.969.0 4.3 4.560.02 0.34
15 72.866.7 15.961.1 4.6 5.060.6 0.55
16 56.161.0 81.1624.5 3.7 2.661.7 0.47
17 71.5625.5 76.263.3 4.2 3.760.9 0.47
18 60.962.1 76.861.4 4.6 3.961.3 0.47
19 34.760.93 227.7622.2 5.7 4.060.6 0.26
aPrimary screening data, expressed as the mean 6 standard deviation for triplicate determinations at a compound concentration of 300 mM. The positive control
compound 27 (See Figure S4 for details) gave a percentage inhibition of 62.762.2 at a concentration of 10 mM.
bMean 6 standard deviations for triplicate measurements. The positive control compound 28 (See Figure S4 for details) gave an IC50 value of 0.3760.1 mM.
cThe highest value of two independent measurements.
dMean DTm, ligand of two independent measurements. The positive control ATP gave a DTm, ligand of 7.2uC at a concentration of 2 mM.
eLigand efficiencies were calculated using the mean mobility shift assay IC50 values [84].
fValue from a single measurement.
doi:10.1371/journal.pone.0065689.t001
Figure 4. Crystal structures of CHK2 in complex with fragment hits. (A) compound 11; (B) compound 12; (C) compound 13; (D) compound
14; (E) compound 15; (F) compound 16; (G) compound 17; (H) compound 18; (I) compound 19. Fragments are shown in cylinder representation
with orange carbon atoms, and the Fo-Fc electron density omit map is shown in green and contoured at 3s. All structural figures were generated
using the graphics program CCP4MG [85].
doi:10.1371/journal.pone.0065689.g004
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addition its amino-group forms an interaction with Glu308 via a
mediating water molecule.
The identification of the three pyrazole fragments was
reassuring, because the pyrazole moiety is well precedented as a
hinge-binding motif in kinase inhibitors [53,54]. Interestingly,
although the pyrazole group in all three hits is the hinge-binding
motif and occupies the same space, the three fragments bind in a
different manner due to the substitution pattern of each compound
(Figure 5B). Compound 16 binds along the hinge with the
pyrazole group forming two hydrogen bond interactions with the
backbone carbonyl and amide groups of Glu302 and Met304
respectively. Compound 17 also binds along the hinge, but is offset
by approximately 26u compared to compound 16. In this
fragment the interaction with the backbone carbonyl of Glu302
is made by the amino-substitution on the pyrazole ring and the
pyrazole group itself interacts with both the amide and carbonyl
groups of Met304, explaining the rotation of the fragment
compared to compound 16. The third pyrazole fragment,
compound 18, binds in an almost orthogonal way with respect
to compound 16 as a result of the thiophene substitution on the
pyrazole 4-position compared to the phenyl substitution on the
pyrazole 3-position in compound 16. However, a detailed
comparison shows that the pyrazole moieties of the two fragments
overlay almost perfectly and make the same interactions with the
hinge. In addition, in both compounds the 5-methyl groups
superimpose very well and bind in a small hydrophobic pocket
near the gatekeeper Leu301.
Comparison of these fragments with known CHK2 inhibitors
shows that the fragments are able to map several interaction hot
spots in the CHK2 ATP-site. Not surprisingly, the different
possible interactions with the hinge are represented in the different
fragments. However, it is interesting to note that the 2-(quinazolin-
2-yl)phenol CHK2 inhibitors, including 3, do not bind to the
hinge through their quinazoline scaffold as observed for fragment
15. Instead, they interact with the hinge via a hydrogen bond
between the phenolic oxygen and the backbone amide group of
Met304, similar to the hydroxyl-hinge interaction of the resorcinol
fragment 12 (Figure 5C) [23]. Intriguingly, although their
respective hydroxyl groups occupy the same space, which is also
the location of the mediating water molecule in the NSC109555-
[55] and PV1019-bound [17] structures, the aromatic parts of
compound 12 and the phenol-moiety in the 2-(quinazolin-2-
yl)phenol inhibitors do not superimpose (Figure 5C). In addition,
the water-mediated interaction of compound 15 with Glu308 was
also observed in compound 10 from the 2-aminopyridine CHK2
inhibitors and exploited as a direct-protein inhibitor interaction in
the 2-(quinazolin-2-yl)phenol CHK2 inhibitor series (Figure 5C).
Furthermore, the interaction with the side chain of Thr367
observed with compounds 11 and 14 (water-mediated) and
compound 12 (direct) is also found in a series of potent
benzimidazole-based CHK2 inhibitors, such as 2-(4-((1-benzylpi-
peridin-4-yl)methoxy)phenyl)-1H-benzo[d]imidazole-5-carboxa-
mide [56] (5, Figure 5D). Finally, the surface of Leu303 and
Met304 binding the furan group in compound 13 has been
postulated as an area for hydrophobic interactions [40], but to
date has not been explored in the rational design of CHK2
inhibitors.
Fragment Hit Expansion
For further confirmation and initial elaboration of the identified
chemotypes, a similarity search was carried out using an in-house
HTS library, comprising approximately 71,000 compounds with
lead-like physicochemical properties. For the search, we selected
the twenty confirmed AlphaScreenTM hits and a further twenty
hits from the fragments with the largest thermal shift in screening.
The resulting set of 40 fragments included the eight mutual and
structurally confirmed fragment hits and the similarity search was
set up to find the ten most similar compounds for each fragment.
Compounds were chosen for further testing based on their
similarity score, similar connectivity as the parent fragment, a
molecular weight larger than that of the parent fragment, and
visual inspection. This yielded 132 compounds in total, for which
the percentage inhibition was determined in the mobility shift
assay at three concentrations. Nineteen compounds were selected
for IC50 determination based on the percentage inhibition data
and on chemotype. Subsequently, four of these compounds (20–
23) were selected for co-crystallization experiments (Figure 6,
Table 2).
Compounds 20 and 21 are both more potent than their parent
fragments 17 and 18. We were able to obtain a crystal structure of
CHK2 complexed with the pyrazolopyridine compound 20, the
more potent of the two, but not with compound 21. Compound
20 binds in a different way to the hinge compared to its parent
pyrazole fragment. Interestingly, it forms hydrogen bonds with the
backbone amide and carbonyl groups of Met304, the gatekeeper
+3 residue via its N7 and N1 atoms, respectively, thus positioning
the pyrazole ring towards the solvent-exposed region of the ATP
binding site (Figure 7A). This is a different binding mode than
observed, for example, in a series of pyrazolopyridine inhibitors of
CHK1 [47], which interact with the hinge region with the
pyrazole facing the gatekeeper and forming hydrogen bonds with
the backbone carbonyl of the gatekeeper +1 residue and the
backbone amide of the gatekeeper +3 residue. A search for
protein-ligand structures exemplifying the binding mode of the
pyrazolopyridine scaffold of compound 20 did not yield any
results; however, IkB kinase subunit b (IKK2) inhibitors contain-
ing a 7-azaindole scaffold have been postulated to bind in
analogous pattern to the kinase hinge [57]. Moreover, a crystal
structure of a 7-azaindole containing inhibitor of spleen tyrosine
kinase (Syk), N-(1-hydroxy-2-methylpropan-2-yl)-1-methyl-3-(1H-
pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide (24), shows
the 7-azaindole binding in this manner (Figures 7B, S3) [58].
Compounds 22 and 23 are both quinoxalines and are related to
the parent quinoxaline fragment compounds 13 and 14,
respectively. Compound 22 is the most potent of the twenty
compounds tested and is modestly more potent than its parent
fragment 13. The crystal structure of compound 22 bound to
CHK2 shows that its binding mode is nearly identical to that of
compound 13. Both bind in the CHK2 ATP-binding site and
interact with the hinge in the same manner and their respective
furan and p-methoxyphenyl groups both extend into a previously
unexplored hydrophobic crevice defined by Leu303, Met304,
Glu305, Leu226, Leu236 and Lys245 (Figure 8A). The main
difference between the two compounds is the orientation of the p-
methoxyphenyl group of compound 22 with respect to the furan
ring of compound 13 (Figure 8B). The p-methoxyphenyl moiety of
compound 22 packs against Leu303, the gatekeeper +2 residue in
CHK2, in a similar manner to the interaction of the trimethox-
yphenyl-groups of the indazole and aminopyrazole-based c-Jun N-
terminal kinase 3 (JNK3) inhibitors SR-3737 and SR-3451 (25)
[59] with Leu148, the gatekeeper +2 residue in JNK3 (Figures 8C,
S3).
A superposition of the compound 22-bound CHK2 structure
with the apo-structure of CHK1 [60] shows that compound 22
would clash with Tyr86, the gatekeeper +2 residue in CHK1
(Figure 8D), suggesting that exploiting this pocket could enhance
the selectivity of the next generation of CHK2 inhibitors.
Intriguingly, we recently showed that the chlorophenyl group of
Fragment Screening of CHK2
PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e65689
one of the early CHK2 selective arylbenzimidazole inhibitors 26
(Figure S3) binds in this region [56], although in a slightly less
extended manner as compared to the p-methoxyphenyl group of
compound 22 (Figure 8B). However, it is very difficult to assess the
contribution to selectivity of binding in this pocket using the
inhibitor 26, because its CHK2 selectivity is most likely dominated
by the unusual binding of the benzamidazole scaffold to the hinge
through a mediating water molecule. Nevertheless, the crystallo-
graphic data, combined with the fact that both the fragment 13
and its follow-up compound 22 are inactive in a CHK1 mobility
shift assay (IC50.200 mM for both compounds), make it enticing
to postulate that this pocket could potentially be exploited to
enhance both affinity and selectivity of future CHK2 inhibitors.
Conclusions
The use of orthogonal techniques in fragment screening and a
subsequent focus on the common hits is seen as a key to success in
fragment screening [61]. However, comparisons between SPR,
NMR and DSF/thermal shift assays [51], high concentration
biochemical screening versus NMR [51], NMR versus SPR [62],
and SPR versus a high-concentration mobility shift assay [63]
revealed a varying degree of correlation between hits discovered
using different screening methods. Here we have used the
biochemical AlphaScreenTM kinase assay and biophysical thermal
shift assay to screen a fragment library for inhibitors of CHK2 and
found a good correlation between the hits identified by each
method. Importantly, the orthogonal use of these two assays
allowed us to quickly focus on the most promising fragment hits,
and would also be very helpful in reducing the false-positive hit
rate in cases where an interference assay is not available or
practical. We have identified a number of chemically different
ligand-efficient fragment hits for CHK2 and determined their
binding mode using X-ray crystallography. It is of interest to point
out that all structural information was obtained using co-
Figure 5. Fragments map interaction hotspots exploited by known CHK2 inhibitors. (A) Superposition of compound 13 (light blue) with
the 2-aminopyridine inhibitor, compound 10 (orange, PDB code 2WTJ) showing both interacting with the CHK2 surface defined by Leu303 and
Met304, an area suggested to be important for hydrophobic interactions. (B) Superposition of the three pyrazole fragments compound 16 (green),
17 (orange) and 18 (light-blue) showing the differences in binding. (C) Superposition of the resorcinol compound 12 (light-blue) and the 2-
(quinazolin-2-yl)phenol inhibitor, compound 3 (pink, PDB code 2XBJ). (D) Comparison of compound 12 (light-blue) with the benzimidazole inhibitor
5 (yellow, PDB code 4A9U). Note that the chlorobenzyl group of 5 is not modeled in the crystal structure and has not been included in the PDB
coordinates.
doi:10.1371/journal.pone.0065689.g005
Fragment Screening of CHK2
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e65689
crystallization experiments, which demonstrates that, with suitable
primary screening options, the crystallographic follow-up of a
fragment-based screening campaign is not necessarily reliant upon
the availability of a soakable crystal system.
Although we allowed a slightly higher molecular weight cut-off
than the 250 Da nowadays typically used in the design of a
fragment library [42,51], interestingly six out of the nine
crystallographically confirmed fragment hits have a molecular
weight below 200 Da and one has a molecular weight of
244.3 Da. With respective molecular weights of 253.3 and
261.3 Da, the other two fragment hits, compounds 13 and 19,
are only marginally larger and well below the higher molecular
weight cut-off (320 Da) of our fragment library. Importantly, all
hits bind to the CHK2 hinge region, including compound 19 from
the category of thermal shift hits and AlphaScreenTM inactives.
This hit category should include any second site binders and
therefore our findings confirm the adenine subpocket as the
dominant fragment-binding site.
Furthermore, we have shown that, in addition to the
interactions with the hinge, these fragments exploit several of the
interaction hot-spots used by advanced CHK2 inhibitors, but do
so in different ways. Because no fragments were found to bind in
other subpockets of the CHK2 ATP binding site, further
development into potent lead molecules through fragment linking
[64,65] is not an option. However, since none of the CHK2
fragment hits is exemplified as a hinge-binding scaffold in the
previously reported CHK2 inhibitors, they could be developed by
merging them with existing CHK2 inhibitors. Furthermore, in
keeping with the majority of advanced fragment-based kinase
inhibitors, such as the B-raf inhibitor PLX4032 (Vemurafenib)
[66], the PKB/Akt inhibitor AZD5363 [67], and the Aurora Janus
kinase 2 inhibitor AT9283 [68], optimization using a fragment
evolution/growing strategy [64] would be the most promising way
to develop our CHK2 fragment hit matter into potent lead
molecules with favorable physicochemical properties.
Moreover, the crystal structures of compound 13 and its follow-
up compound 22 access a hydrophobic area above the hinge not
previously explored in rational CHK2 inhibitor design. We
speculate that this pocket could be exploited to enhance both
potency and selectivity of CHK2 inhibitors. However, although
compounds 13 and 22 have good ligand efficiencies (table 1 and
2), the usefulness of this pocket in CHK2 inhibitor design will need
to be further investigated, starting from more potent but non-
selective CHK2 inhibitors. Together the similar binding mode
observed for JNK3 inhibitors, and the fact that many kinases have
a phenylalanine or tyrosine residue in the gatekeeper +2 position,
suggest that the area above the hinge could also be important in
the design of selective ATP-competitive inhibitors for other kinases
with a small gatekeeper +2 residue.
Materials and Methods
Design of the ICR Fragment Library
To define the fragment library parameters the following
molecular weight (MW) filter was applied: 150 Da,Molecular
weight (MW) ,300 Da, with the MW permitted to increase by a
further 20 Da for specific groups (F, Cl, SO2). In addition, typical
Rule-of-Three-based physicochemical property filters [48] were
used such as, ClogP#3 [69], hydrogen bond acceptors #5 and
hydrogen bond donors #3, a topological polar surface area
(TPSA) #75 A˚2 [70], and the number of rotatable bonds #3.
Furthermore, only compounds with ten or more heavy atoms were
included, compounds were allowed to have 1 to 3 rings with
between 3 and 7 atoms per ring, and a maximum of 1 halogen or
sulfur atom per fragment was permitted. The filters were applied
using the descriptors implemented in MOE 2007.09 [50] and
diverse subset selections were also carried out in MOE. Prior to
Figure 6. Chemical Structures of the four follow-up compounds
selected for crystallography. Compound 20 and 21 both originate
from the pyrazole fragments 17 and 18 and compound 22 and 23 are
both quinoxalines relating to compound 13.
doi:10.1371/journal.pone.0065689.g006
Table 2. Selected follow-up compounds from similarity search.
Compounds selected for
crystallography Mobility shift IC50 (mM)
a
Ligand Efficiency
(kcal mol21 HA21)b IC50 of parent fragment(s) (mM)
20 7.262.9 0.42 76.2
21 21.362.1 0.32 76.8
22 3.661.2 0.34 11.7/36.9
23 14.268.6 0.28 11.7/36.9
aThe IC50 values are expressed as mean 6 standard deviation from triplicate measurements. The positive control compound 28 (See Figure S4 for details) gave an IC50
value of 0.3060.1 mM.
bLigand efficiencies were calculated using the mean mobility shift assay IC50 values.
doi:10.1371/journal.pone.0065689.t002
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purchasing, the final fragment selection was visually inspected to
remove fragments with undesirable structural moieties, such as
known reactive groups, Michael acceptors, and aromatic nitro
groups.
Samples for solubility measurements using nephelometry and
LC-MS analysis were collected from 20 mM samples in 100%
DMSO and made up for analysis in 96-well plates at a final sample
concentration of 500 mM and 2.5% (v/v) DMSO. This allowed for
Figure 7. The binding mode of the pyrazolopyridine compound 20. (A) Crystal structure of CHK2 in complex with compound 20. The
compound is shown in cylinder representation with light-blue carbon atoms, and the Fo-Fc electron density omit map is shown in green and
contoured at 3s. (B) Superposition of compound 20 (light-blue) and the spleen tyrosine kinase inhibitor 24 (pink, PDB ID code 3FQH) [58] showing
they bind in a similar way to the hinge gatekeeper +3 residue.
doi:10.1371/journal.pone.0065689.g007
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80 fragments per well and 16 blank control wells for data
normalization. All nephelometry experiments were carried out
using a NEPHELOstar Galaxy (BMG Labtech GmbH, Orten-
berg, Germany) and were performed in duplicate to minimize
errors. Measurements were collected for each of the plates at a rate
of 1 s per well using a gain of 80 and a beam focus of 2 mm. To
account for the noise in the measurements, the reading of each
well value was normalized by the average of the empty well data
for each plate. The minimum of the two replicate well values was
then taken as the more accurate reading. Compounds with
readings of four standard deviations above the mean of all
measurements were defined as insoluble.
LC-MS measurements were conducted on the same fragment
plates as used for the nephelometry experiments, with the data for
one replicate plate collected in positive ionization mode, while
data for the other replicate plate was collected in negative
ionization mode. Analytical separation was carried out at 30uC on
a Merck Chromolith SpeedROD column (RP-18e, 5064.6 mm)
using a flow rate of 2 mL/min in a 4 min gradient elution with
UV detection at 254 nm. The mobile phase was a mixture of
methanol (solvent A) and water (solvent B), both containing 0.1%
(v/v) formic acid. Gradient elution was as follows: 1:9 (A/B) to 9:1
(A/B) over 2.5 min, 9:1 (A/B) for 1 min, and then reversion back
to 1:9 (A/B) over 0.3 min, finally 1:9 (A/B) for 0.2 min. Positive
Figure 8. The binding mode of the quinoxaline compound 22. (A) Crystal structure of CHK2 in complex with compound 22. The compound is
shown in cylinder representation with yellow carbon atoms, and the Fo-Fc electron density omit map is shown in green and contoured at 3s. (B)
Superposition of the quinoxaline fragment compound 13 (light-blue), compound 22 (yellow) and the arylbenzimidazole CHK2 inhibitor 26 (pink,
PDB ID code 4A9R), showing the fragments bind in a nearly identical manner with their respective furan and p-methoxyphenyl group binding in a
hydrophobic pocket above the hinge, which is also accessed by the chlorophenyl group of the CHK2 inhibitor 26. CHK2 is shown in a
semitransparent surface representation and the location of Leu226, Leu236 and Leu303 are indicated. (C) Superposition of compound 22 (yellow)
and the JNK3 inhibitor 25 (light-green), showing that their respective p-methoxyphenyl and trimethoxyphenyl groups bind in the hydrophobic
pocket above the hinge. (D) Superposition of the compound 22-bound CHK2 structure in yellow and the apo-structure of CHK1 (PDB ID code 1IA8) in
orange, showing the clash of compound 22 with Tyr86, the gatekeeper +2 residue in CHK1.
doi:10.1371/journal.pone.0065689.g008
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and negative ionization was achieved on a 6520 series qToF mass
spectrometer fitted with a MultiMode ionization source (Agilent,
Santa Clara, USA). Fragments that failed LC-MS, or were
identified as insoluble, were flagged as such in our library
documentation and compound database.
Protein Expression and Purification
The coding sequence for full-length human CHK2 (residues 1
to 543) was PCR amplified from the IMAGE clone AU20-A2
(Human Genome Mapping Project) and inserted into the pFastBac
HTa vector, which encodes an N-terminal 6xHis-tag. Recombi-
nant baculovirus was generated according to the Bac-to-BacH
protocols (Invitrogen, Paisley, UK). Sf9 insect cells were grown in
sf-900 II media to a cell density of around 106 cells per mL,
infected with 10 mL to 100 mL of virus per 107 cells and harvested
after 48–72 h. Cell pellets were lyzed by resuspension in lysis
buffer (50 mM HEPES pH 7.4, 250 mM NaCl, 0.1% (v/v) NP40,
1 mM NaF, 10 mM b-glycerophosphate, 0.1 mM Na3VO4) and
incubated on ice for 30 min. Following centrifugation the
supernatant was diluted with 1/7 volume of 8x binding buffer
(160 mM Tris pH 7.9, 4 M NaCl, 40 mM imidazole) and passed
over a column containing His Bind resin (Novagen, Merck
Chemicals Ltd, Nottingham, UK). The column was washed with 8
column volumes (CV) of 1x binding buffer, 3 CV of 0.5x wash
buffer (20 mM Tris pH 7.9, 250 mM NaCl, 30 mM imidazole)
and eluted with 3 CV of elution buffer (20 mM Tris pH 7.9,
500 mM NaCl, 500 mM imidazole). Eluted protein was dialysed
against 20 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM DTT,
0.03% (v/v) Brij-35, 50% (v/v) glycerol and stored at –80uC.
The kinase domain of CHK2 (residues 210-531) was produced
as a GST-fusion protein and purified as previously described [8].
Fragment Screening Using a Biochemical Assay
Full-length CHK2 was screened against the ICR fragment
library consisting of 1869 fragments using a biochemical assay
based on AlphaScreenTM technology [71] in which the CHK2
kinase activity was measured by monitoring the phosphorylation of
a CDC25C peptide using a phospho-specific antibody [40]. Assay
conditions were similar to those described by Hilton et al., but all
fragments were screened at a final concentration of 300 mM.
Amendments to the protocol included a change in the full-length
CHK2 concentration to 2 nM and a final concentration of the
antibody against phosphorylated CDC25C of 0.5 nM. For a
positive control, 4-(2-amino-5-(thiophen-3-yl)pyridin-3-yl)benzoic
acid (27, Figure S4, referred to as compound 19 in Hilton et al.)
[40] was added at a final concentration of 10 mM. The
phosphorylation reaction was performed for 80 min at room
temperature and stopped by the addition of 5 mL of the previously
described detection buffer [40]. Plates were incubated overnight at
room temperature and in the dark, and the assay endpoint was
measured using an EnvisionTM 2103 multilabel reader (Perkin
Elmer Life Sciences, Seer Green, UK). Primary screening data
were analyzed in ActivityBase (IDBS, Guildford, UK). Percentage
inhibition was calculated as follows: 100*(1–(S–B)/(T–B)), where S
represented the counts for each compound well, B the counts in
the wells containing no enzyme, and T the counts in the total
activity wells. The plates were assayed in triplicate and fragments
with a percentage inhibition of 50% or more in at least two out of
the three measurements were defined as initial hits. Initial hits
were re-assayed under the same conditions in triplicate for
reconfirmation. Furthermore, all hits were tested for interference
by repeating the assay in the presence of phosphorylated rather
than unphosphorylated peptide substrate, and for aggregation by
including 0.01% (v/v) TritonTM X-100 in the assay buffer.
IC50 Determination Using a Mobility Shift Assay
For all fragment hits showing no interference and no
aggregation, IC50 values were determined using a microfluidic
assay that monitors the separation of a phosphorylated product
from its substrate. In addition, percentage inhibition and IC50
values for all follow-up compounds were determined in triplicate
using this assay. The assay was performed on an EZ Reader II
(Caliper Life Sciences Ltd, Runcorn, UK) using separation buffer
(#760367 Caliper LS) containing CR-8 (500 nM, #760278,
Caliper LS). An ECHOH 550 acoustic dispenser (Labcyte IncTM,
Dublin, Ireland) was used to generate duplicate eight-point
dilution curves directly into 384-well low-volume polystyrene
assay plates (Corning Life Sciences, New York, USA). For each
compound, a 10 mM stock concentration in 100% DMSO was
used. The total amount of DMSO dispensed per well was 250 nL
to give a final assay concentration of 2.5% (v/v) DMSO and
compounds in the range 0.1–200 mM. For a positive control, 2-[4-
((R)-piperidin-3-ylamino)-quinazolin-2-yl]-phenol (28, Figure S4,
referred to as compound 13 in Caldwell et al.) [23] was used in the
range 0.005–10 mM.
An assay master mix consisting of 6 mL full-length CHK2
(2 nM final concentration), 2 mL peptide 10 (5-FAM-
KKKVSRSGLYRSPSMPENLNRPR-COOH, 1.5 mM final con-
centration, #760354 Caliper LS) and 2 mL ATP (100 mM final
concentration) all diluted in kinase buffer (40 mM HEPES pH 7.5,
40 mM KCl, 1 mM DTT, 2 mM MgCl2 and 0.02% (v/v)
Tween20) was added to the compounds in the assay plate. The
plate was sealed and centrifuged for 1 min at 1000 rpm before
incubation for 1 h at room temperature. The reaction was stopped
by the addition of separation buffer (760367, Caliper LS),
containing 100 mM HEPES pH 7.3, 0.015% (v/v) Brij-35, 5%
(v/v) DMSO, 0.1% (v/v) Coating reagent 3, 0.05 mM and 10 mM
EDTA.
The plate was read on an EZ Reader II, using a 12-sipper chip
(760137-0372R, Caliper LS) with instrument settings of 21.5 psi
and 1750 DV. The percentage conversion of product from
substrate was generated automatically and the percentage
inhibition was calculated relative to blank wells (containing no
enzyme and 2.5% (v/v) DMSO) and total wells (containing all
reagents and 2.5% (v/v) DMSO). IC50 values were calculated from
a four-parameter logistics fit of percentage inhibition versus
concentration using the Studies package (from Dotmatics, Bishops
Stortford, UK).
Fragment Screening Using a Thermal Shift Assay
Thermal shift screening of the ICR fragment library against a
truncated version of CHK2 comprising only the kinase domain
(CHK2-KD), was carried out using an Opticon 2 RT-PCR
machine (Bio-Rad, Hemel Hempstead, UK). The assay buffer
consisted of 0.14 mg/mL (3.9 mM) CHK2-KD, 4.2x SYPROH
Orange protein gel stain (Sigma-Aldrich), 10 mM HEPES
pH 7.5, 50 mM NaCl and 4 mM DTT in a final volume of
50 mL. All experiments were performed in white 96-well
SuperPlate skirted PCR-plates (ABgeneH, Thermo Scientific,
Loughborough, UK). Fragments were screened at a final
concentration of 2 mM in assay buffer containing a final
concentration of 2% (v/v) DMSO and all measurements were
carried out in duplicate. The well contents were mixed by
centrifugation for 2 min at 500 g and pre-equilibrated for 5 min
at 20uC before starting the thermal shift experiment. All melting
curves were generated from 20uC to 95uC, raising the
temperature in steps of 0.5uC and keeping it constant for 15
seconds at each step. The melting temperature of CHK2 in the
absence of a ligand (Tm, 0) was determined by averaging six
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reference melting curves per plate from wells containing the
thermal shift assay buffer and CHK2-KD in 2% (v/v) DMSO.
MgATP (2 mM ATP and 5 mM MgCl2) in the presence of 2%
(v/v) DMSO was used as a positive control. For each
experiment, the data range of the protein unfolding transition
was established using the Excel-based worksheet ‘DSF Analysis’,
made available by the Structural Genomics Consortium (SGC),
Oxford [72], and subsequently fitted with a Boltzmann
sigmoidal equation using GraphPad Prism version 5 (GraphPad
Software, San Diego, California, USA, www.graphpad.com),
from which the melting temperature Tm was calculated. The
change in melting temperature caused by ligand binding,
expressed as the mean from duplicate measurements (DTm,
ligand), was calculated by subtracting Tm, 0 from each melting
temperature obtained in the presence of a ligand (Tm, ligand)
using the DSF-analysis spreadsheet. The hit threshold was
determined by calculating the standard deviation (SD) of the
melting temperatures of CHK2 in the presence of ligand (Tm,
ligand) for every plate. Ligands with a Tm, ligand.mean(Tm, ligand)
+2SD in at least one of the duplicates were defined as hits.
Similarity Search for Fragment Elaboration
A similarity search was performed against an in-house
compound library, which contained 70,877 unique chemical
structures with lead-like physicochemical properties. The 20
confirmed AlphaScreenTM hits and the 28 hits with the largest
thermal shift were selected as probes. After removal of duplicate
fragments this yielded a set of 40 parent structures, which included
the eight crystallographically confirmed fragment hits. A similarity
search was performed for each probe in turn and the 10 most
similar compounds were selected from the compound library. The
search protocol was executed in PipelinePilot 8.0 [73] using
Functional-Class Fingerprints [74] with a diameter of four
(FCFP_4) and similarities between the fingerprints of the
compounds calculated using the Tanimoto coefficient [75].
Crystallization and Structure Elucidation
Co-crystallization experiments with selected fragment hits were
carried out based on conditions described earlier [8]. In brief,
crystallization experiments were performed using the hanging- and
sitting-drop vapor diffusion methods at 4uC. Crystallization drops
were made by mixing 2 mL protein solution (typically 10 mg/mL
CHK2-KD in buffer containing 10 mM HEPES pH 7.5, 250 mM
NaCl, 10 mM DTT, 2 mM EDTA and 2 mM of a fragment hit)
and 2 mL precipitant solution (0.1 M HEPES pH 7.5, 0.2 M
Mg(NO3)2, 10% (v/v) ethylene glycol, 1 mM TCEP and 8–14%
(w/v) PEG 3350) over 0.5 mL of the respective reservoir solution.
Crystals usually grew in 2–5 days and were harvested and
cryoprotected using a cryoprotectant solution containing 0.1 M
HEPES NaOH pH 7.5, 0.1 M NaCl, 0.2 M Mg(NO3)2, 20% (v/v)
ethylene glycol and 10% (w/v) PEG 3350 before flash-freezing in
liquid nitrogen.
The datasets were collected at beamlines I02, I04 and I24 at the
Diamond Light Source (Oxfordshire, UK) and integrated, merged
and scaled using the programs MOSFLM (Leslie, 1992) and
SCALA from the CCP4 suite (Collaborative Computational
Project, Number 4, 1994 [76], see table S1 for data collection
and refinement statistics), except for the data for compound 22,
which were collected on an in-house X8 PROTEUM system
(Bruker AXS Ltd., Coventry, UK), and integrated, merged and
scaled with PROTEUM2. All CHK2 protein-ligand structures
were solved by molecular replacement using PHASER [77] with a
CHK2-inhibitor complex (PDB code 2WTJ) with the inhibitor
and water molecules removed as a search model. The protein-
ligand structures were manually rebuilt in COOT [78] and refined
with BUSTER [79] in iterative cycles. Ligand restraints were
generated with Grade [80] and Mogul [81]. The positioning of the
furan ring in compound 13 was guided using Isostar maps [82]
calculated using data from the Cambridge Structural database and
from the protein databank respectively. The quality of the
structures was assessed with MOLPROBITY [83]. The coordi-
nates of compounds 11–19 and compounds 20 and 22 and their
associated structure factors have been deposited in the Protein
Data Bank with accession codes, 4BDA, 4BDB, 4BDC, 4BDD,
4BDE, 4BDF, 4BDG, 4BDH, 4BDI and 4BDJ, 4BDK, respec-
tively.
Supporting Information
Figure S1 Assay performance in the fragment screen. Assay
reproducibility for the screen in triplicate for all fragments. The
mean values for the total activity ( &)
m) are shown. There were 320 compounds on
(TIF)
Figure S2 IC50 values of the mutual AlphaScreen
TM and
thermal shift hits compared with the three most prominent Tm-
shift hits classed as inactives in the AlphaScreenTM. The figure
shows that the three latter compounds (category 3, shown in
orange) have IC50 values significantly higher than the mutual hits
(category 1, shown in red), consistent with the primary screening
data and are therefore less attractive to follow up. Square symbols
denote compounds for which co-crystal structures with trCHK2
were determined (see Table S1). The IC50 values are indicated as
mean 6 standard deviation from triplicate measurements.
(TIF)
Figure S3 Chemical structures of the spleen tyrosine kinase
inhibitor (24,) the JNK3 inhibitor SR3451 (25) and the early
arylbenzimidazole inhibitor compound (26).
(TIF)
Figure S4 Chemical structures of positive controls (compounds
27 and 28) used in AlphaScreenTM and mobility shift assays.
(TIF)
Table S1 Crystallographic data collection and refinement
statistics for fragment hits and follow-up compounds.
(DOC)
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